Navigation Links
Genzyme Launches Cholestagel(R) in Europe
Date:10/23/2007

used on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including statements about the timing and geographies of Cholestagel's launch, as well as statements concerning Genzyme's plans to seek regulatory approval for Cholestagel in additional geographies. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, the size of the market for the therapy in any particular geography, the sufficiency of reimbursement for the therapy in any particular geography; actions by governmental authorities related to Cholestagel, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Cholestagel(R) are registered trademarks of Genzyme Corporation and WelChol(R) is a registered trademark of Daiichi Sankyo Inc. All rights reserved.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Co
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. Merge launches diagnostic mammography workstation in Europe
5. Einstein Wireless launches cellular alert system
6. Logistics Health launches compliance management tool
7. UW-Madison launches new high-speed research network
8. UWM launches research foundation
9. TeraMedica launches information manager
10. GE Healthcare launches hybrid electronic record
11. Cedara launches new version of DICOM toolkit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... ALBANY, N.Y. , May 1, 2015 ... today that William S. Marth , AMRI,s President ... of America Merrill Lynch 2015 Health Care Conference on ... A live audio webcast of the presentation can ... http://ir.amriglobal.com/events.cfm?CalendarID=2          The webcast will be ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
(Date:4/30/2015)... April 30, 2015 Nitto Avecia, ... announces its increased capacity and production capability to ... client variety and service fulfillment continues to drive ... improve process throughput capacities. , In ... installed downstream process equipment at its Milford, MA ...
(Date:4/30/2015)... Paul G. Allen Family Foundation announced today the award ... of researchers with projects at the frontier of one ... human brain cells in the laboratory. The projects are ... years.  "This new cohort of Allen ... the field of neuronal maturation is at the leading ...
Breaking Biology Technology:AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5
... a technology that allows researchers to test new drugs on ... fortunately for one local company, the federal government is willing ... , ,To improve its technology, InvivoSciences, LLC , a ... National Center for Complementary and Alternative Medicine at ...
... Inc. has reached the public sector with the sale ... Stratton VA Medical Center in Albany, N.Y., a ... now is treating patients with TomoTherapy's cancer-targeting system, the company ... what the company calls conformal radiation therapy that targets tumors ...
... -You're in an elevator next to a venture capitalist who ... first thing about it yet. , ,You have 90 ... the Elevator Pitch Olympics, a yearly event at the ... investors dished out advice and a few hard knocks to ...
Cached Biology Technology:InvivoSciences receives NIH grant for heart technology 29 tips for making 90 seconds count in an investment pitch 2
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... the U.S. should spend roughly $197 million more than it ... public health. The analysis found that the U.S. spends ... the health impacts of climate change, says Marie S. O,Neill, ... adequately address the public health issues related to global warming, ...
... aimed at developing drugs that stop malaria parasites from ... from the Walter and Eliza Hall Institute, named a ... and Science. Dr Baum, a senior postdoctoral fellow ... the molecular mechanisms that control the malaria parasite,s movement. ...
... porpoisesfirst dipped their toes into water, a series of evolutionary ... the larger hoofed animal group. But what happened first, a ... the loss of their ability to walk? A new paper ... debate using a massive data set of the morphology, behavior, ...
Cached Biology News:US needs nearly $200 million more on climate-related health research 2Malaria research wins Jake Baum a Young Tall Poppy award 2Getting a leg up on whale and dolphin evolution 2Getting a leg up on whale and dolphin evolution 3
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Applications: Western blotting Stability: Room temperature, indefinitely ...
... Rabbit Antibody to ARG. Vasopressin ... vasopression peptide. Cells are found in ... fibers are found throughout the hypothalmus ... perfused tissue. Immunogen: ...
Biology Products: